Abbott India Limited share price
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartere…Read more
- Market Cap₹ 55,609 Cr.
- Current Price₹ 26,170.00
- High / Low₹ 30,655 / 25,135
- Stock P/E34.4
- Book Value₹ 2,247
- Dividend Yield2.01 %
- ROCE41.9 %
- ROE34.50 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 759.86
- Price / Book11.65
- OPM26.3 %
- Debt / Equity0.04
- Sales growth (3Y)9.0 %
- Profit growth (3Y)17.8 %
- Promoter holding75.5 %
- EV / EBITDA27.8
- Beta0.06
- All-time high₹ 37,000
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| ABBOTINDIA | +0.17% | -6.10% | +1.20% | -9.84% | -12.28% | +5.20% | +4.08% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Abbott India Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹55,609 crore.
- It trades at 34.4 times its last 12 months' earnings and 11.6 times book value.
- Revenue grew 9.0% a year over the last 3 years, profit 17.8% a year.
- Return on equity was 34.5% and return on capital employed 41.9% in the latest year.
- Debt was 0.04 times shareholders' equity.
- The share price is 14.6% below its 52-week high and down 12.3% over one year.
- Promoters and insiders hold about 75.5%; institutions about 6.9%.
Pros
AI- Strong return on equity: 35.0% on average over the last 3 years.
- Company is almost debt-free (debt is 0.04 times equity).
- Pays a healthy dividend: about 65% of profit last year.
Cons
AI- Trades at 11.6 times its book value.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
- Employees
- 3,679
- Head office
- Mumbai
- NSE industry
- Healthcare
Peer comparison
HealthcareHealthcareDrug Manufacturers - Specialty & Generic
Part ofNifty 500Nifty Midcap 150
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Abbott India | 26,170.00 | 34.4 | 55,609 | 2.01 | 429 | 17.13 | 1,814 | 4.33 | 41.9 | 34.5 | 11.65 | 26.3 | 0.04 | 75.54 | 6,927 | 9.0 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 574 | 29.12 | 4,031 | 12.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 47 Co. | 1,909.45 | 31.4 | 17,624 | 0.33 | 682 | 15.71 | 5,999 | 15.68 | 16.4 | 14.1 | 4.17 | 16.1 | 0.21 | 55.20 | 20,499 | 13.3 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Operating Profit | 426 | 484 | 445 | 462 | 503 |
| Profit before tax | 493 | 546 | 509 | 531 | 572 |
| Net Profit | 366 | 415 | 376 | 395 | 429 |
| EPS in Rs | 172.17 | 195.42 | 176.92 | 185.85 | 201.66 |
Profit & Loss
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 5,347 | 5,847 | 6,407 | 6,927 |
| Operating Profit | 1,147 | 1,406 | 1,645 | 1,825 |
| Interest | 16 | 12 | 11 | 25 |
| Depreciation | 70 | 71 | 72 | 76 |
| Profit before tax | 1,274 | 1,618 | 1,887 | 2,079 |
| Net Profit | 949 | 1,201 | 1,414 | 1,552 |
| EPS in Rs | 446.78 | 565.28 | 665.62 | 730.36 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 |
| Reserves | 3,167 | 3,678 | 4,212 | 4,753 |
| Borrowings | 113 | 83 | 197 | 172 |
| 1,254 | 1,411 | 1,487 | 1,556 | |
| Trade payables | 892 | 1,003 | 1,058 | 1,107 |
| Current liabilities | 1,206 | 1,343 | 1,407 | 1,477 |
| Total Liabilities | 4,556 | 5,193 | 5,917 | 6,502 |
| 234 | 229 | 351 | 333 | |
| Gross block | 355 | 375 | 514 | 511 |
| Accumulated depreciation | 122 | 146 | 164 | 178 |
| Goodwill & intangibles | 8 | 7 | 6 | 4 |
| CWIP | 5 | 10 | 21 | 6 |
| 4,317 | 4,955 | 5,546 | 6,163 | |
| Inventories | 649 | 620 | 882 | 947 |
| Trade receivables | 319 | 319 | 380 | 362 |
| Cash & equivalents | 240 | 292 | 561 | 442 |
| Current assets | 3,025 | 3,246 | 4,763 | 3,771 |
| Total Assets | 4,556 | 5,193 | 5,917 | 6,502 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 893 | 1,213 | 1,012 | 1,319 | |
| Profit for the year | 949 | 1,201 | 1,414 | 1,552 |
| Working capital changes | 23 | 129 | -257 | -70 |
| Direct taxes paid | -341 | -404 | -447 | -540 |
| -148 | -416 | 182 | -371 | |
| Fixed assets purchased | -34 | -48 | -53 | -41 |
| Fixed assets sold | 0 | 0 | 1 | 29 |
| Investments purchased | -5,455 | -4,641 | -2,993 | -4,394 |
| Investments sold | 5,239 | 4,129 | 3,102 | 3,651 |
| -639 | -745 | -925 | -1,066 | |
| Interest paid | -0 | -9 | -7 | -18 |
| Dividends paid | -584 | -691 | -871 | -1,009 |
| Net Cash Flow | 107 | 52 | 269 | -118 |
| Free Cash Flow | 859 | 1,164 | 959 | 1,278 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROE | 29.8% | 34.9% | 35.7% | 34.5% |
| ROCE | 38.5% | 42.3% | 42.1% | 41.9% |
| Operating margin | 21.5% | 24.0% | 25.7% | 26.3% |
| Net margin | 17.8% | 20.5% | 22.1% | 22.4% |
| Debt / equity | 0.04 | 0.02 | 0.05 | 0.04 |
| Current ratio | 2.51 | 2.42 | 3.39 | 2.55 |
| Debtor days | 22 | 20 | 22 | 19 |
| Inventory days | 79 | 70 | 92 | 93 |
| Days payable | 109 | 113 | 110 | 109 |
| Cash conversion cycle | -8 | -23 | 4 | 3 |
| Working capital days | 124 | 119 | 191 | 121 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 75.54%
- Institutions (FII, DII, funds) 6.89%
- Public & others 17.57%
Key dates
- Results announced
- 5 Nov 2026
- Ex-dividend date
- 24 Jul 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
No recent announcements.
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Abbott India Limited
What is the share price of Abbott India Limited today?
What is the market cap of Abbott India Limited?
What is the P/E ratio of Abbott India Limited?
Is Abbott India Limited a good investment?
How can I buy Abbott India Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.